Marisa Wexler, MS,  senior science writer—

The U.S. Food and Drug Administration (FDA) has accepted a proposal from Bellerophon Therapeutics to reduce the size of a Phase 3 clinical trial that’s testing its INOpulse device on people with pulmonary fibrosis (PF) at risk of pulmonary hypertension (PH). The change, made based on analyses from…

Treatment with Pulnovo Medical‘s pulmonary artery denervation (PADN) device improved exercise capacity, blood flow dynamics, and clinical outcomes for pulmonary arterial hypertension (PAH) patients in a clinical trial called PADN-CFDA, the company announced. “The PADN-CFDA results are very important because this was an adequately powered randomized controlled trial,…

Mice that lack a protein called AMPK in the muscle around their blood vessels develop a lethal disease that appears very similar to persistent pulmonary hypertension of the newborn (PPHN), suggesting that AMPK may be a useful therapeutic target in this disease, according to a new study. “This study…

Scores on standardized risk assessments showed a clear treatment effect with Orenitram (treprostinil) after three months in a pulmonary arterial hypertension (PAH) clinical trial, with patients showing risk score improvements being less likely to have clinical worsening later on. The results of this new analysis suggest early changes…

The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) have published a new set of guidelines for the diagnosis and management of pulmonary hypertension (PH). These guidelines simplify diagnostic criteria for PH, emphasizing the importance of early disease detection and the expedited referral of high-risk patients…

More than half of babies born preterm at a center in the Netherlands were found to have pulmonary hypertension (PH), a new study reports. Babies with PH were more likely to develop bronchopulmonary dysplasia (BPD), a breathing disorder where the lungs don’t develop correctly, and survival outcomes were poorer…

Treatment with Adempas (riociguat) improved blood flow measurements in people with pulmonary hypertension and heart failure with preserved ejection fraction (HFpEF) in a clinical trial. Researchers say that further study is needed to determine the effect of Adempas on clinical outcomes like exercise capacity. The study, “…

Diagnostic testing plays an important role in guiding changes in treatment for children with pulmonary arterial hypertension (PAH), suggesting that virtual healthcare visits may not be an adequate substitute for in-person testing for many children with the disease. That’s according to the study, “Factors Determining Change in Treatment for…

Yutrepia, an inhaled formulation of treprostinil, was generally well tolerated and improved the quality of life for people with pulmonary arterial hypertension (PAH) in the Phase 3 INSPIRE clinical trial. The therapy was preferred by nearly all trial participants who switched to it from Tyvaso, an older inhaled…

More than half of people with pulmonary arterial hypertension (PAH) who start daily treatment with oral Opsumit (macitentan) are expected to still be alive after nine years on the therapy, according to a new analysis of data from the SERAPHIN clinical trial and its open-label extension. “These analyses…

Treatment with Uptravi (selexipag) significantly improved blood flow parameters in people with inoperable or persistent chronic thromboembolic pulmonary hypertension (CTEPH) in a Phase 3 clinical trial, although its use did not significantly affect measures of physical abilities. Full trial results are in “Selexipag for the treatment of…

Among people with chronic thromboembolic pulmonary hypertension (CTEPH), risk assessments and treatment patterns prior to surgical procedures do not predict outcomes after surgery, a new study from Sweden shows. The results suggest that most CTEPH patients who don’t undergo surgery remain in the same risk category for at least…